tk88 bet

Ministry of Health publicises prices of Molnupiravir drugs produced in Vietnam

The Drug Administration of Vietnam (DAV) under the Ministry of Health (MoH) has announced the prices of COVID-19 treatment drugs containing active ingredient Molnupiravir produced by three Vietnamese manufacturers.
Ministry of Health publicises prices of Molnupiravir drugs produced in Vietnam ảnh 1Packets of COVID-19 treatment drugs containing active ingredient Molnupiravir produced by Vietnamese manufacturers. (Photo: bostonpharma.com.vn)

Hanoi (VNA) – The Drug Administration of Vietnam (DAV) under the Ministry of Health (MoH) hasannounced the prices of COVID-19 treatment drugs containing active ingredient Molnupiravir produced by threeVietnamese manufacturers.

Accordingly, a pill of Molravir 400mg made by Boston Vietnam Pharma costs 11,550 VND while the prices of Movinavir 200mgmanufactured by Mekophar Chemical Pharmaceutical,and Molnupiravir Stella 400mg produced by Stellapharm J.V Co., Ltd.  are 8,675 VND and 12,500 VND a tablet, respectively.

These drugs are sold to COVID-19 patients for home treatment providedthat they show proof of being infected with coronavirus and prescriptions from doctors.  

The Drug Administration of Vietnam officiallylicensed the three COVID-19 drugs on February 17.

The DAV requested drug manufacturing and registration establishments to produce in accordance with dossiers and documents registered with the Ministry of Health,  coordinate with treatment facilities to strictly comply with current regulations on prescription drugs, monitor the safety, effectiveness, and unwanted effects of drugs on Vietnamese people, and report it regularly.

The DAV also asked the Departments of Health of provinces and centrally-run cities to direct local medical examination and treatment facilities, medical staff, and drug supply establishments to notify patients of the benefits and risks when using these drugs, treatment methods, other drugs that can replace Molnupiravir in treating COVID-19.

During the circulation of the three drugs, based on the monitoring and updating information on the safety and effectiveness of them, the agency may decide to revoke the granted certificates of registration for circulation in line with Clause 1, Article 58 of the Law on Pharmacy.

These drugs are used to treat mild to moderate adult COVID-19 patients with at least one risk factor that could enhance the progression of thedisease, according to the MoH.

꧑ Thedrugs should not be used for pregnant women or those who are planning to become pregnant,nursing women, and children under 18 years old./.

See more

Assoc. Prof. Dr Nguyen Viet Nhung, Dean of Medicine at University of Medicine and Pharmacy, Vietnam National University (VNU) Hanoi, speaks online on Vietnam’s digital transformation strategy in medical education. (Photo: VNA)

ꩲ Forum spotlights AI and digital innovation in healthcare

To achieve its goal of becoming a developed nation by 2045, Vietnam is prioritising the integration of AI and digital tools into the training of future doctors, said Assoc. Prof. Dr. Nguyen Viet Nhung, Dean of Medicine at University of Medicine and Pharmacy, Vietnam National University (VNU) Hanoi.
A banner on the side of a car urges people to quit smoking for their own health and that of their loved ones (Photo: VNA)

🍎 Sharp tobacco tax hike urged to safeguard youths, community health

A 2023 report by the Vietnam Health Economics Association estimated that the total cost of tobacco-related healthcare and economic losses reached 108 trillion VND (4.14 billion USD) annually – equivalent to 1.14% of GDP and five times higher than the budget revenue generated by the tobacco industry.
On the morning of May 26, 2025, following bilateral talks at the Presidential Palace, President Luong Cuong (first, right) and French President Emmanuel Macron (first, left) witness the exchange of cooperation documents between leaders of ministries, agencies, and enterprises from both countries. In the photo: Ngo Chi Dung, General Director and Chairman of the Board of Viet Nam Vaccine Company (VNVC) (second, right), and Zainab Sadat Qayyum, President of Sanofi Southeast Asia – India, exchange the cooperation agreement on the transfer of Sanofi’s vaccine production technology to VNVC’s vaccine and biologicals plant. (Photo: VNVC)

🤪 Vietnam, France collaborate in vaccine production technology transfer

Under the agreement, VNVC and Sanofi will gradually implement technology transfers to enable domestic production of several key Sanofi vaccines that are widely used in Vietnam. In addition, Sanofi will support VNVC in training human resources and quality management in vaccine research and manufacturing.
{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|{tk88 bet}|